Toceranib
Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].
Product Specifications
CAS Number
356068-94-5
Product Name Alternative
SU11654; PHA 291639E
UNSPSC
12352005
Hazard Statement
H315, H319
Target
C-Kit; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Toceranib.html
Purity
97.41
Solubility
DMSO : 2.5 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL
Smiles
O=C(NCCN1CCCC1)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C
Molecular Formula
C22H25FN4O2
Molecular Weight
396.46
Precautions
H315, H319
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDGFRβ; VEGFR2/KDR/Flk-1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
